Aarti Drugs Analyst Review 2027: Record Quarter, Profit Up 83% and a P/E Half the Industry’s
- November 17, 2026
- Posted by: Chaitanya Auti
- Category: Market
Aarti Drugs Stock Snapshot (16 Nov 2026 close)
- Current Market Price (CMP): ₹501.25
- 52-Week High / Low: ₹527.50 / ₹318.95
- Market Capitalisation: ₹4,580 crore
- P/E Ratio vs Industry P/E: 20.0 vs 40.7
- Latest Quarter (Q2 FY27) Revenue: ₹826 crore
- Latest Quarter (Q2 FY27) Net Profit: ₹82.8 crore
Quick Answer: The Aarti Drugs analyst review 2027 has no verified, dated brokerage target to cite, so it rests on a strong set of reported numbers. Q2 FY27 was the company’s best quarter ever: revenue rose 27% to ₹826 crore, EBITDA jumped 63% to ₹138 crore and profit grew 83% to ₹82.8 crore. Better API pricing lifted the EBITDA margin to 16.6%, its highest in nearly six years. At ₹501.25, the stock trades at a P/E of about 20, roughly half the pharma industry average.
This Aarti Drugs analyst review 2027 comes after the strongest quarter in the company’s history. Anyone checking the Aarti Drugs share price target 2027 will find no verified brokerage call in recent months, but the September 2026 quarter speaks clearly. Revenue, EBITDA and profit all hit record highs, and the shares jumped about 7% on result day.
Aarti Drugs is one of India’s larger makers of active pharmaceutical ingredients (APIs), with growing formulation and specialty chemical businesses. The stock, at ₹501.25, is up about 57% from its 52-week low and sits just 5% below its high of ₹527.50.
Click Here – Get Free Investment Predictions
Analyst Ratings and Targets in the Aarti Drugs Analyst Review 2027
We could not find a dated, named brokerage rating or target price on Aarti Drugs from recent months that we could verify. Some aggregator sites show consensus figures, but without a named source and date we have not used them.
| Brokerage | Rating | Target Price | Date |
|---|---|---|---|
| No verified recent coverage | – | – | As of November 2026 |
The Aarti Drugs analyst review 2027 therefore relies on the company’s Q2 FY27 results, investor presentation and shareholding data.
September 2026 Quarter in the Aarti Drugs Analyst Review 2027
| Metric (Consolidated) | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Revenue from Operations | ₹826.2 crore | ₹652.8 crore | +27% |
| EBITDA | ₹137.9 crore | ₹84.4 crore | +63% |
| EBITDA Margin | 16.6% | 12.9% | +370 bps |
| Net Profit | ₹82.8 crore | ₹45.2 crore | +83% |
| H1 FY27 Net Profit | ₹132.9 crore | – | – |
Price did most of the work. Stronger API pricing and better realisations drove the margin to 16.6%, which management called its best in nearly six years. Volume growth was only 5% in the quarter and 3% for the first half, below the company’s earlier target of about 10%.
That split matters for this Aarti Drugs analyst review 2027. Price-led gains can fade if API prices soften, while volume-led growth is more durable. The next few quarters need more volume to lock in the improvement.
Where Aarti Drugs Revenue Comes From
An Aarti Drugs share analysis covers three businesses:
- APIs: The core. The company makes bulk drugs across anti-diabetic, antibiotic, anti-inflammatory and anti-fungal categories and sells them to formulation makers in India and abroad. The standalone business, mostly APIs, posted ₹708.9 crore of revenue in Q2 FY27, up 22%.
- Formulations: Finished medicines sold under its own and partner brands. This revenue rose 58% to ₹130 crore in Q2 FY27.
- Specialty chemicals: Chemicals made through the Sayakha unit. Revenue nearly doubled to ₹71.8 crore as the plant ramped up.
API margins depend on raw material costs, many of which come from China, and on global selling prices. When input costs fall or selling prices rise, margins expand quickly, as Q2 showed. Moving up the chain into formulations gives steadier margins over time.
The balance sheet is sound. Debt to equity has fallen from 0.52 in FY23 to about 0.37, and operating cash flow of ₹253.5 crore in FY26 covered the year’s ₹173 crore capex.
Growth Drivers Behind the Aarti Drugs Analyst Review 2027
Margin reset: If API pricing holds, the 16.6% margin could set a new base for FY27 earnings.
Formulation growth: A 58% jump shows the push into finished drugs is gaining pace.
Sayakha ramp-up: Specialty chemicals nearly doubled in a year and still have room to grow.
Volume recovery: Returning to the 10% volume target would add growth on top of better pricing.
The Bear Case in the Aarti Drugs Analyst Review 2027
- Price dependence: Most of Q2’s gain came from pricing, which can reverse.
- Weak volumes: 3% first-half volume growth is well short of the 10% goal.
- China exposure: Key raw materials come from China, so supply or price shocks hit costs.
- Quarter-to-quarter swings: Specialty chemical revenue fell 13% from Q1 to Q2 even as it doubled year on year.
- Regulatory audits: API plants face inspections from Indian and foreign drug regulators.
Compare API and Pharma Stocks on the Univest Screener
Stock at a Glance in the Aarti Drugs Analyst Review 2027
| Parameter | Value |
|---|---|
| Market Cap | ₹4,580 crore |
| P/E (TTM) / Industry P/E | 20.0 / 40.7 |
| Price to Book | 2.72 |
| Return on Equity | 13.6% |
| Debt to Equity | 0.37 |
| Dividend Yield | 0.40% |
| FY26 Revenue / Net Profit | ₹2,568 crore / ₹194.9 crore |
A P/E ratio of 20 against a pharma industry average of 40.7 is a wide discount. Part of it reflects the commodity-like nature of APIs compared with branded drugs. Part of it reflects years of flat profit: net profit was ₹205 crore in FY22 and ₹195 crore in FY26. Compared with the wider Nifty Pharma pack, the stock is priced as a cyclical rather than a compounder.
Shareholding Changes Through 2026
| Holder | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|
| Promoters | 54.72% | 55.03% | 55.03% | 54.43% | 54.07% |
| FIIs | 2.69% | 2.15% | 1.58% | 1.52% | 2.26% |
| DIIs | 9.90% | 10.12% | 10.22% | 10.29% | 10.24% |
| Public | 32.69% | 32.70% | 33.18% | 33.75% | 33.43% |
Promoter holding has eased slightly to 54.07% over two quarters. Foreign investors returned in the September quarter, lifting their stake to 2.26% from 1.52%. Domestic institutions have held steady near 10%. In the Aarti Drugs analyst review 2027, the FII return is worth watching after the record quarter.
Dates and Data to Track After the Aarti Drugs Analyst Review 2027
- Q3 FY27 results (around early February 2027): Whether the 16.6% margin holds.
- Volume growth: Progress toward the 10% target.
- API price trends: Global pricing for key molecules.
- Formulation and specialty chemicals: Continued growth from both units.
- Brokerage coverage: Any new named reports after the record quarter.
Summing Up the Aarti Drugs Analyst Review 2027
The Aarti Drugs analyst review 2027 shows a company that just posted its best quarter on record. Profit up 83%, margins at a six-year high and fast growth in formulations and specialty chemicals made the Q2 FY27 results stand out. A P/E of about 20 is modest next to the industry.
The catch is that pricing drove most of the gain while volumes lagged. For the Aarti Drugs stock outlook 2027, steady margins and a pick-up in volumes would show the improvement is lasting rather than a price spike.
Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions
What does the Aarti Drugs analyst review 2027 show?
The Aarti Drugs analyst review 2027 shows a record quarter with no verified brokerage coverage. Q2 FY27 revenue rose 27% to ₹826 crore and profit jumped 83% to ₹82.8 crore. The EBITDA margin reached 16.6%, the best in nearly six years. The stock trades at a P/E of about 20.
Is there an Aarti Drugs share price target 2027?
We could not verify a dated target price from a named brokerage in recent months. Some websites show consensus numbers, but without a clear source we have not used them. Investors can track margins, volumes and API prices instead. The current price of ₹501.25 is near the 52-week high of ₹527.50.
Which Q2 FY27 numbers drive the Aarti Drugs analyst review 2027?
Consolidated revenue rose to ₹826.2 crore from ₹652.8 crore. EBITDA increased 63% to ₹137.9 crore. Net profit rose 83% to ₹82.8 crore. First-half profit reached ₹132.9 crore.
Why does the Aarti Drugs analyst review 2027 credit pricing for the profit jump?
Stronger API pricing and better realisations drove most of the gain. The EBITDA margin rose 370 basis points to 16.6%. Formulation revenue also grew 58% and specialty chemicals 92%. Volume growth was only 5%, so pricing did most of the work.
Which businesses does the Aarti Drugs analyst review 2027 cover?
The company makes active pharmaceutical ingredients in anti-diabetic, antibiotic, anti-inflammatory and anti-fungal categories. It also sells finished formulations and specialty chemicals through its Sayakha unit. Standalone revenue, mostly APIs, was ₹708.9 crore in Q2 FY27. FY26 consolidated revenue was ₹2,568 crore.
What risks does the Aarti Drugs analyst review 2027 flag?
Dependence on API pricing is the main risk, since prices can fall. Volume growth of 3% in the first half is well below the 10% target. Raw materials from China expose the company to supply shocks. Regulatory inspections of plants are another risk.
What are the next triggers for the Aarti Drugs stock outlook 2027?
The Q3 FY27 results, due around early February 2027, will show whether the 16.6% margin holds. Progress toward 10% volume growth is key. Continued growth in formulations and specialty chemicals would broaden earnings. New named brokerage coverage would also add to the Aarti Drugs analyst review 2027.